Clinical Trials · NCT01412424
Efficacy and Safety of Octreotide (MYCAPSSA™ [Formerly Octreolin™]) for Acromegaly
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Chiasma, Inc.
- Enrollment
- 155
- Start date
- Mar 2012
- Locations
- 36 sites, 13 countries
- Primary endpoint
- Percentage of Responders at the End of the Core Treatment Period